Ann: Opthea to Present at Ophthalmology Innovation Summit in US-OPT.AX, page-14

The presentation wasn't given by Megan.

"The presentation titled "A first-in-human Phase 1/2a study of the novel VEGF-C/D inhibitor OPT-302 alone and in combination with ranibizumab in patients with wet AMD” was presented by Dr. Pravin Dugel, Managing Partner of Retinal Consultants of Arizona, Clinical Professor at the University of Southern California Eye Institute, Keck School of Medicine, and member of Opthea’s Clinical Advisory Board and Clinical Investigator"

But clearly its had an impact.